FDA/NIH instability threatens biotech capital and IPO timelines
Key Questions
What FDA and NIH changes are creating uncertainty for biotech?
A ~4% FDA budget cut and staffing reductions, plus NIH reforms, heighten PDUFA uncertainty. This contributes to volatility and capital risks over 6-24 months.
How is Replimune's RP1 decision significant?
Replimune's RP1 has a PDUFA date of April 10 with 33% ORR in melanoma, serving as a barometer for FDA direction amid staffing issues at the Center for Biologics. Biotech views it as the first indicator post recent FDA leadership changes.
What are the national security concerns with Chinese biotech?
Warnings highlight Chinese biotech advancements as significant threats to national security. Increased China scrutiny adds to regulatory risks for biotech capital and IPO timelines.
~4% FDA budget cut/staffing + NIH reforms + China nat sec warnings heighten PDUFA uncertainty (IOBT bankruptcy, Replimune RP1 Apr10 33% ORR melanoma barometer); countered by NH right-to-try/flex regs + EMA/FDA AI principles (Generate/Diagens). Volatility/capital risks 6-24mo; monitor PDUFAs/appropriations/China scrutiny.